A major AI drug-discovery claim reaches a new stage
Isomorphic Labs, the Google DeepMind spinoff built around AlphaFold-driven drug discovery, says it is preparing to start human trials of medicines designed with its AI technology. The update came from company president Max Jaderberg at WIRED Health in London, where he said the startup has built a “broad and exciting pipeline of new medicines” and is now gearing up to enter the clinic.
The statement matters because it moves the AI-drug story from laboratory promise toward clinical accountability. For several years, companies across the biotech sector have argued that machine learning can speed the discovery of better medicines. Human testing is where that thesis becomes measurable.
What Isomorphic is building on
Isomorphic Labs was founded in 2021 as a spinoff from Google DeepMind. Its work is closely tied to AlphaFold, the AI system that transformed protein structure prediction. In 2020, DeepMind presented AlphaFold 2, and the following year an open-source version was released for broad scientific use. In 2024, DeepMind and Isomorphic Labs introduced AlphaFold 3, extending the system beyond proteins in isolation to include molecules such as DNA and RNA and their interactions with proteins.
That progression is central to drug discovery. According to the source text, the platform can help predict how a small molecule may bind to a target and what else it might bind to. Those are core questions in designing medicines that are both effective and safe.
The scientific backdrop is substantial. The source says AlphaFold has predicted the structure of virtually all 200 million proteins known to researchers and has been used by more than 2 million people across 190 countries. Its impact was recognized at the highest level when Demis Hassabis and John Jumper received the Nobel Prize for chemistry.
